Lv31
228 积分 2021-08-17 加入
Bispecific T cell engager therapy for refractory rheumatoid arthritis
8小时前
待确认
CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma
1个月前
已完结
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
1个月前
已完结
The CD58-CD2 axis in cancer immune evasion
1个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
1个月前
已完结
Targeting immune cell circuits and trafficking in inflammatory bowel disease
1个月前
已完结
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
1个月前
已完结
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
1个月前
已完结
肠道巨噬细胞在炎症性肠病中的研究进展
1个月前
已完结
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
3个月前
已完结
皖公网安备34019202002308
